Match!
Katrien Devreese
Ghent University
PathologyImmunologyAntiphospholipid syndromeLupus anticoagulantMedicine
143Publications
24H-index
1,684Citations
What is this?
Publications 139
Newest
#1Lisa N. van der Vorm (Maastricht University Medical Centre)H-Index: 3
#2Dana Huskens (Maastricht University Medical Centre)H-Index: 7
Last. Katrien Devreese (UGent: Ghent University)H-Index: 24
view all 7 authors...
Abstract Introduction Increased levels of circulating von Willebrand Factor (VWF) in its active, platelet-binding conformation have been implicated in the pathogenesis of several thrombotic conditions as well as bleeding conditions characterized by severe thrombocytopenia. However, it is unclear whether the proportion of activated VWF in the circulation also plays a role in patients with mild to moderate bleeding without thrombocytopenia. Methods Citrated plasma samples were collected from 145 p...
Source
#1Dana Huskens (Maastricht University Medical Centre)H-Index: 7
#2Li Li (Maastricht University Medical Centre)H-Index: 1
Last. Katrien Devreese (Ghent University Hospital)H-Index: 24
view all 7 authors...
Abstract Introduction Light transmission aggregometry (LTA) is the gold standard for diagnosing bleeding disorders. Although LTA is laborious, requires large volumes of blood and is relatively insensitive to small changes in platelet function, there is still no competing alternative approach to replace LTA for the diagnosis of platelet bleeding disorders. Materials and methods This study investigates the correlation between flow cytometry-based whole blood platelet activation test (WB-PACT) and ...
Source
PURPOSE OF THE REVIEW This review focuses on the laboratory tests necessary for the diagnosis of antiphospholipid syndrome (APS). For the interpretation of the results of the tests for antiphospholipid antibodies (aPL), understanding of all pitfalls and interferences is necessary. RECENT FINDINGS Progress has been made on the standardization of aPL tests and current guidelines for detection of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), and antibeta2-glycoprotein I antibodies (a...
Source
Background: Although guidelines do not recommend antiphospholipid antibodies testing after 60 yo, recent data reported late onset antiphospholipid syndrome (APS). Objectives: To comparatively analyse the clinical, laboratory features and outcomes in 695 cases with primary APS between patients older and younger than 70 yo. Methods: we have performed an international study within the framework of the International Registry of primary APS patients treated with Hydroxychloroquine, HIBISCUS (an ongoi...
Source
#1Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
#2Anna Vantilborgh (Ghent University Hospital)H-Index: 6
Last. Katrien Devreese (Ghent University Hospital)H-Index: 24
view all 7 authors...
Source
The diagnosis of antiphospholipid syndrome (APS) relies on the detection of circulating antiphospholipid antibodies (aPL). Currently, lupus anticoagulant (LAC), anticardiolipin (aCL), and antibeta2-glycoprotein I antibodies (aβ2GPI) IgG or IgM are included as laboratory criteria if persistently present. Progress has been made on the standardization of tests as guidelines on LAC testing and immunological assays for aCL and aβ2GPI are published. However, LAC measurement remains a complicated proce...
Source
#2Tinne MonteyneH-Index: 8
Last. Katrien Devreese (UGent: Ghent University)H-Index: 24
view all 5 authors...
Source
#1Tinne Monteyne (Ghent University Hospital)H-Index: 8
#2Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
Last. Katrien Devreese (UGent: Ghent University)H-Index: 24
view all 3 authors...
Source
#1Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
#2Katrien Devreese (UGent: Ghent University)H-Index: 24
BACKGROUND: Direct oral anticoagulants (DOAC) interfere with lupus anticoagulant (LAC) testing. DOAC-StopTM (D-S) represents a preanalytical strategy to cope with this issue. OBJECTIVES: To assess D-S's ability to remove DOAC from plasma and overcome DOAC interference in LAC assays and to evaluate D-S's applicability in a representative patient cohort with routine LAC request. METHODS: Apixaban (30-933 ng/ml), edoxaban (31-1060 ng/ml), rivaroxaban (35-1020 ng/ml) and dabigatran (20-360 ng/ml) we...
Source
BACKGROUND: Thrombin generation (TG) is a better determinant of the overall function of the haemostatic system than routinely used clotting time-based assays. Nowadays, TG is widely used in hemostasis research teams, for both clinical and basic research. However, there is significant variability between laboratories regarding preanalytics, reagents, TG protocol, analysis interpretation and normalization. OBJECTIVES: In order to document the extent of variation in the methodology of TG, we aim to...
Source
12345678910